Suppr超能文献

2018 - 2020年中国猪圆环病毒2型流行病学分析及防控策略

Epidemiological Analysis From 2018 to 2020 in China and Prevention Strategy of Porcine Circovirus Type 2.

作者信息

Huang Ying, Chen Xianghong, Long Yunzhi, Yang Liu, Song Wenbo, Liu Jinjin, Li Qianqian, Liang Gong, Yu Daobing, Huang Chao, Tang Xibiao

机构信息

Diagnostic Center Department, Wuhan Keqian Biology Co., Ltd., Wuhan, China.

出版信息

Front Vet Sci. 2021 Nov 16;8:753297. doi: 10.3389/fvets.2021.753297. eCollection 2021.

Abstract

Porcine circovirus type 2 (PCV2) is one of the smallest known animal viruses and is the main pathogen of PCV-associated diseases (PCVAD). Epidemiological surveillance results have shown that the PCV2 infection rate is on the rise in China, thus, PCV2 disease prevention and control has become a huge challenge for the Chinese swine industry. We collected clinical samples from multiple different provinces in China from 2018 to 2020 and found that the positive rate of PCV2 was 53% (3619/6872), identity between the cloned 62 genes was 84.4-100% and identity between the cloned 62 ORF2 sequences and reference sequence was 72.9-99.8%. Genetic evolution analysis found that PCV2d accounted for 79% (49/62 samples), PCV2a for 12.9% (8/62 samples), PCV2b for 8% (5/62 samples), and PCV2c and PCV2e genotypes were not found. However, most commercial PCV2 subunit vaccines are based on the PCV2a genotype, and there are very few vaccines based on PCV2b or PCV2d. Therefore, the homologous and heterologous protection ability of PCV2b and PCV2d Cap proteins based on the baculovirus against the PCV2b and PCV2d infections was evaluated, which is expected to design and develop excellent PCV2 protein vaccine candidates. This study found that both PCV2b and PCV2d Cap proteins can increase the level of humoral immunity and cellular immune response in mice. Importantly, both PCV2b and PCV2d cap proteins can provide homologous and heterologous protection against the PCV2b and PCV2d viruses. Overall, this study provides a reference for the prevention and control of PCVAD in mainland China and the development of PCV2 vaccines.

摘要

猪圆环病毒2型(PCV2)是已知最小的动物病毒之一,是猪圆环病毒相关疾病(PCVAD)的主要病原体。流行病学监测结果表明,中国PCV2感染率呈上升趋势,因此,PCV2疾病的防控已成为中国养猪业面临的巨大挑战。我们于2018年至2020年从中国多个不同省份收集临床样本,发现PCV2阳性率为53%(3619/6872),克隆的62个基因之间的同一性为84.4 - 100%,克隆的62个ORF2序列与参考序列之间的同一性为72.9 - 99.8%。遗传进化分析发现,PCV2d占79%(49/62个样本),PCV2a占12.9%(8/62个样本),PCV2b占8%(5/62个样本),未发现PCV2c和PCV2e基因型。然而,大多数商业化的PCV2亚单位疫苗基于PCV2a基因型,基于PCV2b或PCV2d的疫苗很少。因此,评估了基于杆状病毒的PCV2b和PCV2d Cap蛋白对PCV2b和PCV2d感染的同源和异源保护能力,有望设计和开发出优秀的PCV2蛋白疫苗候选物。本研究发现,PCV2b和PCV2d Cap蛋白均可提高小鼠的体液免疫和细胞免疫反应水平。重要的是,PCV2b和PCV2d Cap蛋白均可对PCV2b和PCV2d病毒提供同源和异源保护。总体而言,本研究为中国大陆PCVAD的防控及PCV2疫苗的研发提供了参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a04/8635018/b3ede47cf32d/fvets-08-753297-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验